As pioneers in gene therapy, we are proud of the medical and technological innovation represented in valoctocogene roxaparvovec, which is possible because of the scientists who did the early research, clinical investigators, the hemophilia community and the people who work here.BioMarin partnered with ARUP, a laboratory with 35 years of experience supporting hospitals, physicians, and patients with unparalleled quality and service including two prior FDA companion diagnostic approvals, to develop this test.